Cerebrolysin vs Pinealon
A side-by-side research comparison of Cerebrolysin and Pinealon across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Cerebrolysin | Pinealon |
|---|---|---|
| Full name | Cerebrolysin (Brain-Derived Peptide Preparation) | Pinealon (Glu-Asp-Arg) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | Investigational | Research compound |
| Mechanism | Contains fragments mimicking NGF, BDNF, GDNF, CNTF. Enhances synaptic plasticity, promotes neuronal sprouting, reduces amyloid-beta, and stabilizes calcium homeostasis. | As a peptide bioregulator it is proposed to penetrate cells and interact with DNA to modulate gene expression in neural tissue, reducing oxidative damage and supporting neuronal survival and protein synthesis. |
| Molecular weight | <10,000 Da (peptide fraction) | ~418 Da |
| Half-life | 4-6 hours | Short (small peptide, rapidly metabolized) |
| Bioavailability | High (IM/IV) | Injectable in research; intranasal also used |
| Typical dose | 5-30 mL | ~5-10 mg per course day (research) |
| Frequency | Daily for 10-20 days | Daily during a short course |
| Route | Intramuscular or IV | Subcutaneous or intranasal |
Cerebrolysin reported benefits
- Neurotrophic support
- Stroke recovery
- Memory improvement
- Neuroprotection
- Synaptic plasticity
- Approved in 40+ countries
Pinealon reported benefits
- Neuroprotective and antioxidant effects (research)
- Supports cognition under stress/aging
- May support healthy sleep-wake regulation
- Short-course bioregulator profile
Related comparisons
Research and educational reference only. Not medical advice.